Almirall and EpimAb partner to develop bispecific antibody therapies
Pharmaceutical Technology
OCTOBER 12, 2023
Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.
LegoChem partners Glycotope to develop antibody-drug conjugate
Pharmaceutical Technology
OCTOBER 17, 2023
LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).
Antibody 
130
130 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LegoChem, Amgen partner to develop antibody drug conjugates
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). As per the terms of the agreement, LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.
Antibody 130
130 
Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK
Pharma Mirror
APRIL 18, 2023
Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
Licensing 130
130 
OncoVerity eyes cusatuzumab development in AML after licensing rights
Pharmaceutical Technology
MARCH 28, 2023
On March 27, OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, which came from both argenx and the venture of UCHealth and the University License Equity Holdings.
Licensing 130
130 
Biogen licenses Denali’s amyloid beta programme for Alzheimer’s
Pharmaceutical Technology
APRIL 13, 2023
Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. ATV: Aβ uses Denali’s ATV technology to cross the blood-brain barrier (BBB) and increase brain exposure to antibodies.
Licensing 130
130 
BioNTech licenses bispecific antibody for cancer in $1 billion deal
BioPharma Reporter
NOVEMBER 7, 2023
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech companyâs bispecific antibody cancer drug PM8002 in all territories except for Greater China.
Antibody 98
98 
AbbVie announces acquisition of DJS Antibodies for $255m
Pharmaceutical Technology
OCTOBER 21, 2022
AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
Antibody 217
217 
AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In May, the company supplied the first doses of the antibody therapy to Swiss hospitals for Covid-19 prevention.
Antibody 264
264 
US FDA approves Eisai-Biogen’s antibody for Alzheimer’s
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.
FDA Approval 246
246 
Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Antibody 279
279 
Syncromune and Eucure enter antibody licence deal
Pharmaceutical Technology
OCTOBER 19, 2022
Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.
Antibody 130
130 
Renaissance Pharma licenses Hu14.18 for neuroblastoma
Drug Discovery World
AUGUST 2, 2023
Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18
Licensing 98
98 
Efficiently develop antibody-based therapeutics
Drug Discovery World
OCTOBER 12, 2022
In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing. . Approaches for monoclonal antibody formulation .
Antibody 52
52 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.”
Antibody 130
130 
Partnership could enhance antibody discovery for cancer research
Drug Discovery World
JULY 21, 2023
Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. The post Partnership could enhance antibody discovery for cancer research appeared first on Drug Discovery World (DDW).
Antibody 98
98 
Adcendo and Duality Biologics sign license deal for ADC platform
Pharmaceutical Technology
JANUARY 6, 2023
Danish biotech company Adcendo has entered into a licence agreement with Duality Biologics on the next-generation antibody-drug conjugates (ADC) platform. The post Adcendo and Duality Biologics sign license deal for ADC platform appeared first on Pharmaceutical Technology.
Licensing 130
130 
Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab
BioSpace
OCTOBER 21, 2021
The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies.
Licensing 73
73 
New eBook: Efficiently develop antibody-based therapeutics
Drug Discovery World
OCTOBER 12, 2022
In the Quality by Design (QbD) approach to antibody-based therapeutics development, stability characterisation —the probability of a protein unfolding or denaturing— is performed to ensure that structure and function are preserved throughout development and manufacturing. . Approaches for monoclonal antibody formulation .
Antibody 52
52 
Astellas to support development of Taysha’s gene therapy programmes
Pharmaceutical Technology
OCTOBER 25, 2022
Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.
Gene Therapy 264
264 
Which diseases are poised to benefit from therapeutic antibody development
Drug Discovery World
NOVEMBER 14, 2023
DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. This is not only made clear by the fact that the global cancer mAbs market size was valued at $55.6
Antibody 59
59 
Accelerated development for Covid-19 monoclonal antibody
Drug Discovery World
JANUARY 3, 2023
A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . Hugo Fry, CEO of RQ Bio, comments: “We’re delighted that one of our discovered antibodies is now at the core of an innovative AstraZeneca investigational medicine reaching clinical trials.” .
Antibody 52
52 
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
DECEMBER 21, 2022
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
Licensing 81
81 
Advancing antibody discovery with AI
Drug Discovery World
NOVEMBER 2, 2023
DenovAI is the second start-up to launch from the global pharma consortium AION Labs – an organisation that aims to improve the drug discovery and development process through the use of AI and other computational technologies. RA: How laborious and expensive are current antibody discovery efforts? KS: In short, incredibly so.
Antibody 83
83 
Three trends in the antibody-drug conjugate (ADC) market
Drug Discovery World
JUNE 1, 2023
Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.
Antibody 98
98 
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
BioTech 365
JUNE 22, 2021
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates Expanded agreement grants Iksuda access to LegoChem Biosciences’ next generation ADC platform for up … Continue reading (..)
Licensing 52
52 
Junshi Biosciences, Dr. Reddy’s partner to develop and market toripalimab
Pharmaceutical Technology
MAY 8, 2023
Shanghai Junshi Biosciences and Dr. Reddy’s Laboratories have partnered for the development and commercialisation of the anti-PD-1 monoclonal antibody, toripalimab, in 21 countries. The company may also choose to expand the scope to license toripalimab in New Zealand, Australia, and in nine other countries.
Development 130
130 
US FDA grants fast track designation for Jasper’s antibody to treat SCID
Pharmaceutical Technology
SEPTEMBER 16, 2022
The US Food and Drug Administration (FDA) has granted fast track designation to Jasper Therapeutics’ antibody, JSP191, for the treatment of severe combined immunodeficiency (SCID) patients who undergo allogeneic hematopoietic stem cell transplant. . The antibody was also analysed in a total of more than 110 healthy subjects and patients. .
Antibody 130
130 
Telix revives Olaratumab development with positive preclinical data
Pharmaceutical Technology
APRIL 17, 2023
Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. Olaratumab will be denoted as TLX300 in Telix’s development pipeline. Telix has demonstrated proof-of-concept (PoC) and will now progress to first-in-human clinical studies.
Development 130
130 
BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES
The Pharma Data
JUNE 2, 2022
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.
Antibody 52
52 
Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines
BioTech 365
NOVEMBER 16, 2021
Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines SAN DIEGO and BASEL, Switzerland, Nov.
Licensing 40
40 
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
The Pharma Data
JANUARY 11, 2021
a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
Antibody 52
52 
Evaxion and ExpreS²ion partner to develop new CMV vaccine
Pharmaceutical Technology
DECEMBER 6, 2022
Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1.
Vaccination 130
130 
Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy
BioTech 365
OCTOBER 21, 2021
Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy … Continue reading →
Licensing 52
52 
AstraZeneca buys into startup RQ Bio’s COVID antibodies
pharmaphorum
MAY 18, 2022
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on.
Antibody 98
98 
Regeneron and CytomX partner to develop bispecific cancer therapies
Pharmaceutical Technology
NOVEMBER 18, 2022
Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. Under the deal, the companies will work together on the discovery activities for identifying and validating the conditionally active bispecific antibodies.
Development 130
130 
Plant-based biopharma firm iBio licenses novel antibody targeting regulatory T cells
BioPharma Reporter
SEPTEMBER 2, 2021
Anti-CD25 antibodies have emerged as one of the most promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.
Antibody 111
111 
Synaffix secures additional ADC technology licensing deals
BioPharma Reporter
JANUARY 6, 2023
Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.
Licensing 52
52 
Biotheus, Hansoh Expand Partnership in $694M ADC Deal
BioSpace
MARCH 14, 2024
Hansoh Pharma is licensing Biotheus’ anti-EGFR/cMet bispecific antibody to develop antibody-drug conjugates. The Chinese biotechs are broadening their collaboration.
Antibody 80
80 
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
BioTech 365
JANUARY 11, 2021
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development SAN DIEGO–(BUSINESS WIRE)–AvantGen, Inc.,
Licensing 52
52 
Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies
Pharmaceutical Commerce
FEBRUARY 20, 2024
As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.
Dermatology 52
52 
BioNTech and OncoC4 team up on novel checkpoint antibody
BioPharma Reporter
MARCH 21, 2023
BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4âs next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications.
Antibody 52
52 
Antibody fragment-based drug could slow geographic atrophy
Drug Discovery World
AUGUST 4, 2023
CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). The company’s first of several therapeutic candidates in development, CDR404, targets MAGE-A4 and is anticipated to enter the clinic in 2024.
Antibody 52
52 License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
The Pharma Data
MARCH 31, 2023
AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. i for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, Notes CMG901 CMG901 is a novel antibody drug conjugate targeting Claudin 18.2, a promising therapeutic target in gastric cancers.
Licensing 40
40 
Let's personalize your content